Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment

Biological Chemistry

Volumn 386, Issue 6, 2005, Pages 535-540

  Werner, Anne ^a   Röhm, Klaus Heinrich ^a   Müller, Hans Joachim ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Acute lymphoblastic leukemia; Antiasparaginase antibodies; Epitope mapping; Phage display; SPOTs

Indexed keywords

ASPARAGINASE; BACTERIAL ENZYME; EPITOPE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; BACTERIAL STRAIN; BLOOD SAMPLING; EPITOPE MAPPING; ESCHERICHIA COLI; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNITY; INTERMETHOD COMPARISON; METHODOLOGY; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN SYNTHESIS;

AMINO ACID SEQUENCE; ASPARAGINASE; DRUG HYPERSENSITIVITY; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; ESCHERICHIA COLI; IMMUNOGLOBULIN G; LEUKEMIA, LYMPHOCYTIC, ACUTE; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY;

EID: 26844525474     PISSN: 14316730     EISSN: 14316730     Source Type: Journal    
DOI: 10.1515/BC.2005.063     Document Type: Article

References (32)

1. Ahlke, E., Nowak-Göttl, U., Schulze-Westhoff, P., Werber, G., and Börste, H. (1997). Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br. J. Hematol. 96, 675-681.
2. Asselin, B., Gelber, R., and Sallan, S. (1993). Relative toxicity of E. coli L-asparaginase (ASP) and PEG-asparaginase (PEG) in newly diagnosed childhood acute lymphoblastic leukemia (ALL). Med. Pediatr. Oncol. 21, 556.
3. Aung, H.P., Bocola, M., and Röhm, K.H. (2000). Dynamics of a mobile loop at the active site of E. coli asparaginase. Biochim. Biophys. Acta 1481, 349-59.
4. Avramis, V.I., Sencer, S., Periclou, A.P., Sather, H., Bostrom, C., Cohen, L.J., Ettinger, A.G., Ettinger, L.J., Franklin, J., Gaynon, P.S., et al. (2002). A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol-conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 99, 1986-1994.
5. Becker, F.F. and Broome, J.D. (1967). L-Asparaginase: inhibition of early mitosis in regenerating rat liver. Science 156, 1602-1603.
6. Becker, F.F. and Broome, J.D. (1969). L-Asparaginase: inhibition of endogenous RNA polymerase activity in regenerating liver. Arch. Biochem. Biophys. 130, 332-336.
7. Broome, J.D. (1968a). Studies on the mechanism of tumor inhibition by L-asparaginase. J. Exp. Med. 127, 1055-1072.
8. Broome, J.D. (1968b). Factors which may influence the effectiveness of L-asparaginase as tumor inhibitors. Br. J. Cancer 22, 595.
9. Cooney, D. and Handschuhmacher, R. (1970). L-Asparaginase and L-asparagine metabolism. Annu. Rev. Pharmacol. 10, 421-440.
10. Craig, L., Sanschagrin, P.C., Rozek, A., Lackie, S., Kuhn, L.A., and Scott, J.K. (1998). The role of structure in antibody cross-reactivity between peptides and folded proteins. J. Mol. Biol. 281, 183-201.
11. Dellinger, C.T. and Miale, T.D. (1976). Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures. Cancer 38, 1843-1846.
12. Desai, N., Amylon, M., Schwenn, MR., Laver, J., and Murphy, L. (1997). Outcome of advanced stage (III-IV) lymphoblastic non-Hodgkin's lymphoma - a Pediatric Oncology Group (POG) study. Med. Pediatr. Oncol. 29, 356 (Abstract O-140).
13. Duval, M., Suciu, S., Ferster, A., Rialland, X., Nelken, B., Lutz, P., Benoit, Y., Robert, A., Manel, A.M., Vilmer, E., et al. (2002). Comparison of Escherichia coli-asparaginase with Erwiniaasparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer - Children's Leukemia Group phase 3 trial. Blood 99, 2734-2739.
14. Evans, W.E., Tsiatis, A., Rivera, G., Murphy, S.B., Dahl, G.V., Denison, M., Crom, W.R., Barker, L.F., and Mauer, A.M. (1982). Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 49, 1378-1383.
15. Hall, J.G. (1970). The partitioning of L-asparaginase between blood and lymph. Recent Results Cancer Res. 33, 75-80.
16. Hrushesky, W.J., Slavik, M., Penta, J., and Muggia, F. (1976). The 'other' asparaginase. Med. Pediatr. Oncol. 2, 441-442.
17. Kabsch, W. and Sander, C. (1983). Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22, 2577-2637.
18. Kurtzberg, J., Asselin, B., Poplack, D., Grebanier, A., Chen, R., Franklin, A., Scudiery, D., and Fisherman, J. (1993). Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients an asparaginase therapy. Proc. Am. Assoc. Cancer Res. 34, 304.
19. Moola, Z.B., Scawn, M.D., Atkinson, T., and Nicholls, D.J. (1994). Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes. Biochem. J. 302, 921-927.
20. Müller, H.J., Löning, L., Horn, A., Schwabe, D., Gunkel, M., Schrappe, M., von Schütz, V., Henze, G., da Palma, J.C., Ritter, J., et al. (2000). Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br. J. Haematol. 110, 379-384.
21. Müller, H.J., Beier, R., Löning, L., Blütters-Sawatzki, R., Dörffel, W., Maass, E., Müller-Weihrich, S., Scheel-Walter, H.G., Scherer, F., Stahnke, K., et al. (2001). Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase Medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br. J. Haematol. 114, 794-799.
22. Otten, J., Suciu, S., Lutz, P., Benoit, Y., Robert, A., Thyss, A., Plouvier, E., Ferster, A., Mechinaud, F., Mazingue, F., et al. (1996). The importance of L-asparaginase (A'ASE) in the treatment of acute lymphoblastic leukemia (ALL) in children: results of the EORTC 58881 randomized phase III trial showing greater efficiency of Escherichia coli (E. coli) as compared to Erwinia (ERW) A'ASE. Blood 88 (Suppl. I/I), 669a.
23. Pacquement, H., Philippe, N., Mechinaud, F., Robert, A., Vilmer, E., Francotte, N., and Millot, F. (1997). Importance of L-asparaginase (Asp), detrimental effects of additional cytosine-arabinoside (Ara-C) and of iv 6-mercaptopurine (6-MP) in the treatment of lymphoblastic non-Hodgkin lymphoma (LBNHL): results of the EORTC 58881 randomized trial. In: SIOP XXIX, Abstract P-160, p. 429.
24. Park, Y.K., Abuchowski, A., Davis, S., and Davis, F. (1981). Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct. Anticancer Res. 1, 373-376.
25. Reineke, U., Sabat, R., Volk, H.D., and Schneider-Mergener, J. (1998). Mapping of the interleukin-10/interleukin-10 receptor combining site. Protein Sci. 7, 951-960.
26. Sallan, E., Hitchcock-Bryan, S., Gelber, R., Cassady, J., Frei, E., and Nathan, G. (1983). Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 43, 5601-5607.
27. Sobin, L.H. and Kidd, J.G. (1965). A metabolic difference between two lines of lymphoma 6C3HED cells in relation to asparaginase. Proc. Soc. Exp. Biol. Med. 119, 325-327.
28. Swain, A.L., Jaskölski, M., Housset, D., Rao, J.K.M., and Wlodawer, A. (1993). Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy. Proc. Natl. Acad. Sci. USA 90, 1474-1478.
29. Van Regenmortel, M.H.V. (1996). Mapping epitope structure and activity: from one-dimensional prediction to four-dimensional description of antigenic specificity. Methods 9, 465-472.
30. Wang, B., Relling, M.V., Storm, M.C., Woo, M.H., Ribeiro, R., Pui, C.H., and Hak, L.J. (2003). Evaluation of immunologic cross-reaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 17, 1583-1588.
31. Woo, M.H., Hak, L.J., Storm, M.C., Evans, W.E., Sandlund, J.T., Rivera, G.K., Wang, B., Pui, C.H., and Relling, M.V. (1998). Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 12, 1527-1533.
32. Yoshimoto, T., Nishimura, H., Saito, Y., Sakurai, K., Kasimaki, Y., Wada, H., Sako, M., Tsujino, G., and Inada, Y. (1986). Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia. Jpn. J. Cancer Res. 77, 1264-1270.